HomeFoodKerry building out biotech capabilities

Kerry building out biotech capabilities

TRALEE, IRELAND — Kerry Group has introduced one acquisition and the settlement to finish one other which can be anticipated to provide it a broader footprint in biotechnology and increase its experience, know-how portfolio and manufacturing capabilities.

The first acquisition includes Enmex, a Tlalnepantla de Baz, Mexico-based enzyme producer. Enmex provides a number of bio-process options for meals, beverage and animal diet markets. Kerry stated Enmex has a complementary enzyme portfolio and robust manufacturing infrastructure which can be anticipated to help in Kerry’s growth of its fermentation and enzyme manufacturing capabilities into Latin America.

Kerry acquired Enmex for roughly €62 million ($70.4 million) on Dec. 14, 2021.

“Enzymes are increasingly playing a vital role as biocatalysts in the food, beverage and pharmaceutical industries, where they deliver many benefits, including improved product quality, increased process efficiency, and reduced food waste, through both minimization of waste and valorisation of waste streams,” stated Neil Cracknell, chief government officer of Kerry Applied Health and Nutrition. “This strategic acquisition of Enmex will complement Kerry’s existing enzyme portfolio and build on our strength in enzymes for modifying cereals and grains. We see enzymes playing a critical role in helping achieve Kerry’s vision to create a world of sustainable nutrition, which is about providing better nutrition, with better processes, which have less impact on our earth’s resources.”

Kerry additionally has agreed to accumulate c-LEcta, a Leipzig, Germany-based biotechnology innovation firm that focuses on precision fermentation, optimized bio-processing and bio-transformation for the creation of high-value focused enzymes and components. The firm primarily is understood for its improvements within the pharmaceutical market but additionally has a powerful pipeline of purposeful bioactives throughout meals, beverage and different client markets.

The transaction features a 92% stake in c-LEcta at a purchase order value of roughly €137 million ($154.9 million).

“The food and pharmaceutical industries are on the cusp of a new wave of innovation where new developments in biotechnology, synthetic biology and precision fermentation are radically transforming these sectors,” stated Albert McQuad, PhD, chief science and know-how officer at Kerry. “c-LEcta is a leader in these new technologies, which includes fermentation-based products such as disruptive new enzymes, and the strategically compelling combination with Kerry will accelerate our innovation capabilities in enzyme engineering, fermentation and bio-process development. Our broad market reach across food and pharma markets, combined with our deep enzyme applications expertise and integrated ingredient technology design, will enable and accelerate the growth potential of c-LEcta’s strong portfolio and technology capabilities while also supporting us in the creation of tastier, more sustainable and healthier products.”

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments